AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe - AstraZeneca (NYSE:AZN)

AstraZeneca reported positive HPP trial data while Enhertu gained EU approval for HER2-positive solid tumors.

Raccontata dabenzinga.com